Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$5.73
+0.23 (+4.18%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-100.0M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.1B
P/E
114.6x
↑EV/EBITDA
40.5x
↑ROE
1.0%
↑Gross Margin
77.0%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-2.1%
FCF CAGR
—
FCF margin
-18.4%
FCF / Net income
-6.42x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $544.0M · net income $15.6M · FCF $-100.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $544.0M | $544.0M | $585.5M | $565.4M | $579.4M |
| Net Income | $15.6M | $15.6M | $74.6M | $-42.9M | $33.5M |
| EBITDA | $42.7M | $42.7M | $65.7M | $1.3M | $78.9M |
| EPS | 0.04 | 0.04 | 0.21 | -0.11 | 0.09 |
| Gross Margin | 77.0% | 77.0% | 78.3% | 76.3% | 76.2% |
| Operating Margin | 1.0% | 1.0% | 4.4% | -1.0% | 1.1% |
| Net Margin | 2.9% | 2.9% | 12.7% | -7.6% | 5.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.04 | 0.01 | 0.01 |
| Current Ratio | 1.93 | 1.93 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-100.0M | $-100.0M | $-210.0M | $-8.6M | $21.7M |
| Returns | |||||
| ROE | 1.0% | 1.0% | 4.8% | -2.6% | 2.0% |
| Valuation | |||||
| P/E | 114.60 | 114.60 | 37.36 | — | 91.44 |
| EV/EBITDA | 40.53 | 40.53 | 38.01 | 1753.79 | 33.47 |
| P/B | 1.29 | 1.29 | 1.79 | 1.75 | 1.82 |
| Growth & Yield | |||||
| Revenue Growth | -7.1% | -7.1% | 3.5% | -2.4% | — |
| EPS Growth | -78.8% | -78.8% | 281.7% | -227.7% | — |
| Dividend Yield | 0.4% | 0.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
125.7%
EPS terminal req.
$0.51
Spread vs growth
-204.6%
5Y implied EPS CAGR
69.3%
EPS terminal req.
$0.62
Spread vs growth
-148.2%
10Y implied EPS CAGR
36.5%
EPS terminal req.
$0.99
Spread vs growth
-115.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-19.9%
Start / end P/E
34.4x → 129.6x
EPS bridge
0.21 → 0.04
Residual
-217.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.